Palleiko Benjamin L, CEO of KalVista Pharmaceuticals Inc. (KALV), has demonstrated a consistent pattern of selling company shares over the past year, according to SEC Form 4 filings. With a total of 30 trades recorded, all transactions have been sales, amounting to a cumulative value of $1,538,597.99. Notably, 11 of these sales occurred in recent months, underscoring a sustained divestment trend. For instance, on March 9, 2026, Palleiko sold shares valued at $107,632.81, following a $156,197.27 sale on February 23, 2026, and a $15,570 transaction on February 18, 2026. These sales are part of a broader pattern that includes earlier transactions, such as a $120,423.94 sale on December 8, 2025, and a $147,153.94 sale on November 24, 2025.
The filings reveal no purchases by Palleiko during this period, indicating a clear bias toward reducing his equity position in KalVista. The transactions are primarily categorized as sales ("S") or involve the exercise of derivative securities ("M"), with no acquisitions reported. This activity is concentrated solely within KalVista Pharmaceuticals, suggesting a focused approach to divesting holdings in the company. While the reasons behind these sales are not disclosed, the data highlights a significant reduction in Palleiko’s stake in KalVista, reflecting a consistent and measurable trend in his insider trading activity.
AI-assisted summary